stay updated
Explore the latest news from Khondrion and its team.
Khondrion press releases
Khondrion shares progress of sonlicromanol development programme at Mitochondrial Medicine 2020 virtual conference
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...
Khondrion to present at Mitocon’s 10th Italian Meeting on Mitochondrial Diseases
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that...
Khondrion announces new Scientific Advisory Board
Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that it has...
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA
Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome. Khondrion, a...
Khondrion appoints Herma Renkema as Chief Early Development Officer
NIJMEGEN, the Netherlands – Wednesday July 1st, 2020 Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...
Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease
Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential...
our stories
Disease spotlight: Leigh disease
Simple functions such as blinking and breathing are actions that we take for granted. However, for those living with Leigh...
Q&A with Rob van Maanen
1. Tell us about your career before joining Khondrion.I qualified as a Medical Doctor from the University of Utrecht and worked clinically in the...
Disease spotlight: Cognition and mitochondrial disease
Cognition is an important function of the brain so we can gain knowledge and understanding. These mental processes include thinking, knowing,...
MELAS Syndrome
Classic MELAS syndrome (Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes), MIDD (maternally inherited diabetes mellitus...
Interview with Julien Beyrath, Chief Scientific Officer at Khondrion
1. Tell us all about your career before joining Khondrion I studied pharmacology and molecular biology at the University of Strasbourg in France,...
CEO Jan Smeitink on Khondrion’s development program and plans for 2020
On Friday 10th January 2020, CEO Jan Smeitink participated in the Annual MitoAction Town Hall Meeting alongside other companies and organisations,...
Reflections on the Mitochondrial Medicine 2019 Conference
Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the Mitochondrial Medicine conference held from 11-13 December 2019 at the...
Mitochondrial Medicine 2019
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
Reflections on SSIEM annual symposium 2019 – Building Bridges
Reflections on SSIEM annual symposium 2019 – Building Bridges Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the...